Table 3.
Effect of pre-treatment with unlabelled PHNO or raclopride on [11C]-3-PHNO binding. The table presents data from control rats (no pre-treatment; n = 3), and rats administered unlabelled PHNO (1 mg/kg; n = 4), or the D2/3 antagonist raclopride (2 mg/kg; n = 4) i.v. five minutes before [11C]-3-PHNO administration. Data were collected 60 minutes later and are expressed as uptake units (mean±SD). The percentage reduction in uptake units relative to control values is presented and results of one-way analysis of variance (ANOVA) analyses for each ROI are also provided.
| Control | PHNO mean±SD (%) |
Raclopride mean±SD (%) |
ANOVA F(2,10); p |
|
|---|---|---|---|---|
| Striata | 2.168±0.28 | 0.378±0.07 (83%) | 0.362±0.05 (83%) | 164.1; <0.001 |
| Olfactory bulbs | 1.082±0.07 | 0.302±0.07 (72%) | 0.292±0.05 (73%) | 179.3; <0.001 |
| Olfactory tubercles | 0.846±0.11 | 0.352±0.02 (58%) | 0.348±0.02 (59%) | 78.0; <0.001 |
| Thalamus | 0.620±0.05 | 0.377±0.07 (39%) | 0.379±0.06 (39%) | 18.6; 0.001 |
| Hypothalamus | 0.660±0.02 | 0.302±0.08 (54%) | 0.352±0.06 (47%) | 30.6; <0.001 |
| Prefrontal cortex | 0.461±0.00 | 0.400±0.03 (13%) | 0.378±0.04 (18%) | 6.5; 0.021 |
| Somatosensory cortex | 0.505±0.01 | 0.373±0.05 (26%) | 0.374±0.04 (26%) | 12.3; 0.004 |
| Entorhinal cortex | 0.427±0.03 | 0.367±0.05 (14%) | 0.347±0.03 (19%) | 4.06; 0.061 |
| Hippocampus | 0.402±0.01 | 0.343±0.04 (15%) | 0.326±0.05 (19%) | 3.9; 0.066 |
| Medulla with Pons | 0.706±0.05 | 0.330±0.02 (30%) | 0.354±0.07 (31%) | 12.4; 0.004 |
| Inferior colliculi | 0.709±0.04 | 0.300±0.10 (53%) | 0.382±0.08 (50%) | 56.2; <0.001 |
| Superior colliculi | 0.476±0.02 | 0.335±0.06 (58%) | 0.328±0.04 (46%) | 23.9; <0.001 |
| Cerebellum | 0.459±0.02 | 0.327±0.05 (29%) | 0.325±0.03 (29%) | 12.9; 0.003 |